Generic Anti-cancer Injectables Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Bevacizuma
1.2.3 Rituximab
1.2.4 Herceptin
1.2.5 Paclitaxel
1.2.6 Others
1.3 Market by Channel
1.3.1 Global Generic Anti-cancer Injectables Market Share by Channel: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Generic Anti-cancer Injectables Market Perspective (2017-2028)
2.2 Generic Anti-cancer Injectables Growth Trends by Region
2.2.1 Generic Anti-cancer Injectables Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2017-2022)
2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2023-2028)
2.3 Generic Anti-cancer Injectables Market Dynamics
2.3.1 Generic Anti-cancer Injectables Industry Trends
2.3.2 Generic Anti-cancer Injectables Market Drivers
2.3.3 Generic Anti-cancer Injectables Market Challenges
2.3.4 Generic Anti-cancer Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic Anti-cancer Injectables Players by Revenue
3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2017-2022)
3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2017-2022)
3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2021
3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
3.7 Date of Enter into Generic Anti-cancer Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic Anti-cancer Injectables Breakdown Data by Type
4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2017-2022)
4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2023-2028)
5 Generic Anti-cancer Injectables Breakdown Data by Channel
5.1 Global Generic Anti-cancer Injectables Historic Market Size by Channel (2017-2022)
5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Channel (2023-2028)
6 North America
6.1 North America Generic Anti-cancer Injectables Market Size (2017-2028)
6.2 North America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
6.3 North America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Generic Anti-cancer Injectables Market Size (2017-2028)
7.2 Europe Generic Anti-cancer Injectables Market Size by Country (2017-2022)
7.3 Europe Generic Anti-cancer Injectables Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2017-2028)
8.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Country (2017-2022)
8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Generic Anti-cancer Injectables Market Size (2017-2028)
9.2 Latin America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
9.3 Latin America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2017-2028)
10.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2017-2022)
10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Generic Anti-cancer Injectables Introduction
11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.1.5 Teva Recent Development
11.2 Viatris
11.2.1 Viatris Company Detail
11.2.2 Viatris Business Overview
11.2.3 Viatris Generic Anti-cancer Injectables Introduction
11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.2.5 Viatris Recent Development
11.3 Biocon
11.3.1 Biocon Company Detail
11.3.2 Biocon Business Overview
11.3.3 Biocon Generic Anti-cancer Injectables Introduction
11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.3.5 Biocon Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Generic Anti-cancer Injectables Introduction
11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.4.5 Amgen Recent Development
11.5 Sandoz (Novartis)
11.5.1 Sandoz (Novartis) Company Detail
11.5.2 Sandoz (Novartis) Business Overview
11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.5.5 Sandoz (Novartis) Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.6.5 Pfizer Recent Development
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Company Detail
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.7.5 Qilu Pharmaceutical Recent Development
11.8 Jiangsu Hansoh
11.8.1 Jiangsu Hansoh Company Detail
11.8.2 Jiangsu Hansoh Business Overview
11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.8.5 Jiangsu Hansoh Recent Development
11.9 CTTQ
11.9.1 CTTQ Company Detail
11.9.2 CTTQ Business Overview
11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.9.5 CTTQ Recent Development
11.10 Jiangsu Hengrui
11.10.1 Jiangsu Hengrui Company Detail
11.10.2 Jiangsu Hengrui Business Overview
11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.10.5 Jiangsu Hengrui Recent Development
11.11 CSPC
11.11.1 CSPC Company Detail
11.11.2 CSPC Business Overview
11.11.3 CSPC Generic Anti-cancer Injectables Introduction
11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.11.5 CSPC Recent Development
11.12 Innovent Biologics
11.12.1 Innovent Biologics Company Detail
11.12.2 Innovent Biologics Business Overview
11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2017-2022)
11.12.5 Innovent Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Bevacizuma
Table 3. Key Players of Rituximab
Table 4. Key Players of Herceptin
Table 5. Key Players of Paclitaxel
Table 6. Key Players of Others
Table 7. Global Generic Anti-cancer Injectables Market Size Growth by Channel (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Generic Anti-cancer Injectables Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Generic Anti-cancer Injectables Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Generic Anti-cancer Injectables Market Share by Region (2017-2022)
Table 11. Global Generic Anti-cancer Injectables Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Generic Anti-cancer Injectables Market Share by Region (2023-2028)
Table 13. Generic Anti-cancer Injectables Market Trends
Table 14. Generic Anti-cancer Injectables Market Drivers
Table 15. Generic Anti-cancer Injectables Market Challenges
Table 16. Generic Anti-cancer Injectables Market Restraints
Table 17. Global Generic Anti-cancer Injectables Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Generic Anti-cancer Injectables Market Share by Players (2017-2022)
Table 19. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2021)
Table 20. Ranking of Global Top Generic Anti-cancer Injectables Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Generic Anti-cancer Injectables Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Generic Anti-cancer Injectables Product Solution and Service
Table 24. Date of Enter into Generic Anti-cancer Injectables Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2017-2022)
Table 28. Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2023-2028)
Table 30. Global Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
Table 31. Global Generic Anti-cancer Injectables Revenue Market Share by Channel (2017-2022)
Table 32. Global Generic Anti-cancer Injectables Forecasted Market Size by Channel (2023-2028) & (US$ Million)
Table 33. Global Generic Anti-cancer Injectables Revenue Market Share by Channel (2023-2028)
Table 34. North America Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
Table 44. Teva Company Detail
Table 45. Teva Business Overview
Table 46. Teva Generic Anti-cancer Injectables Product
Table 47. Teva Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 48. Teva Recent Development
Table 49. Viatris Company Detail
Table 50. Viatris Business Overview
Table 51. Viatris Generic Anti-cancer Injectables Product
Table 52. Viatris Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 53. Viatris Recent Development
Table 54. Biocon Company Detail
Table 55. Biocon Business Overview
Table 56. Biocon Generic Anti-cancer Injectables Product
Table 57. Biocon Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 58. Biocon Recent Development
Table 59. Amgen Company Detail
Table 60. Amgen Business Overview
Table 61. Amgen Generic Anti-cancer Injectables Product
Table 62. Amgen Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 63. Amgen Recent Development
Table 64. Sandoz (Novartis) Company Detail
Table 65. Sandoz (Novartis) Business Overview
Table 66. Sandoz (Novartis) Generic Anti-cancer Injectables Product
Table 67. Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 68. Sandoz (Novartis) Recent Development
Table 69. Pfizer Company Detail
Table 70. Pfizer Business Overview
Table 71. Pfizer Generic Anti-cancer Injectables Product
Table 72. Pfizer Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Qilu Pharmaceutical Company Detail
Table 75. Qilu Pharmaceutical Business Overview
Table 76. Qilu Pharmaceutical Generic Anti-cancer Injectables Product
Table 77. Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 78. Qilu Pharmaceutical Recent Development
Table 79. Jiangsu Hansoh Company Detail
Table 80. Jiangsu Hansoh Business Overview
Table 81. Jiangsu Hansoh Generic Anti-cancer Injectables Product
Table 82. Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 83. Jiangsu Hansoh Recent Development
Table 84. CTTQ Company Detail
Table 85. CTTQ Business Overview
Table 86. CTTQ Generic Anti-cancer Injectables Product
Table 87. CTTQ Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 88. CTTQ Recent Development
Table 89. Jiangsu Hengrui Company Detail
Table 90. Jiangsu Hengrui Business Overview
Table 91. Jiangsu Hengrui Generic Anti-cancer Injectables Product
Table 92. Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 93. Jiangsu Hengrui Recent Development
Table 94. CSPC Company Detail
Table 95. CSPC Business Overview
Table 96. CSPC Generic Anti-cancer InjectablesProduct
Table 97. CSPC Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 98. CSPC Recent Development
Table 99. Innovent Biologics Company Detail
Table 100. Innovent Biologics Business Overview
Table 101. Innovent Biologics Generic Anti-cancer InjectablesProduct
Table 102. Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
Table 103. Innovent Biologics Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Generic Anti-cancer Injectables Market Share by Type: 2021 VS 2028
Figure 2. Bevacizuma Features
Figure 3. Rituximab Features
Figure 4. Herceptin Features
Figure 5. Paclitaxel Features
Figure 6. Others Features
Figure 7. Global Generic Anti-cancer Injectables Market Share by Channel in 2021 & 2028
Figure 8. Hospital Case Studies
Figure 9. Retail Case Studies
Figure 10. Generic Anti-cancer Injectables Report Years Considered
Figure 11. Global Generic Anti-cancer Injectables Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Generic Anti-cancer Injectables Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Generic Anti-cancer Injectables Market Share by Region: 2021 VS 2028
Figure 14. Global Generic Anti-cancer Injectables Market Share by Players in 2021
Figure 15. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2021
Figure 17. North America Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. North America Generic Anti-cancer Injectables Market Share by Country (2017-2028)
Figure 19. United States Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Generic Anti-cancer Injectables Market Share by Country (2017-2028)
Figure 23. Germany Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. France Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. U.K. Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Italy Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Russia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Nordic Countries Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Generic Anti-cancer Injectables Market Share by Region (2017-2028)
Figure 31. China Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Japan Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. South Korea Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Southeast Asia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. India Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Australia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Generic Anti-cancer Injectables Market Share by Country (2017-2028)
Figure 39. Mexico Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Brazil Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Generic Anti-cancer Injectables Market Share by Country (2017-2028)
Figure 43. Turkey Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Saudi Arabia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Teva Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 46. Viatris Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 47. Biocon Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 48. Amgen Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 49. Sandoz (Novartis) Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 50. Pfizer Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 51. Qilu Pharmaceutical Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 52. Jiangsu Hansoh Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 53. CTTQ Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 54. Jiangsu Hengrui Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 55. CSPC Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 56. Innovent Biologics Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
